Sparks commentary - SynAct Pharma

Healthcare

Sparks - SynAct Pharma

More on this equity
SynAct Pharma (STO: SYNACT) appoints Ann Kristin Led as CFO
Published by Jyoti Prakash, CFA

SynAct Pharma has appointed Ann Kristin Led as chief financial officer, effective 1 March 2026, bolstering its finance function ahead of several important clinical and corporate catalysts. She takes over from Björn Westberg, who stepped down in January 2026, with financial controller Malin Wikstrand having served as interim CFO during the transition.

Ms Led brings broad life sciences finance experience from senior positions at MedTrace Pharma, MC2 Therapeutics and Lundbeck, where her responsibilities included capital raising, licensing transactions and establishing scalable financial infrastructures. Her arrival coincides with a key period for SynAct, with the Phase IIb ADVANCE readout expected in Q226 and potential partnering discussions for its lead programme, resomelagon, likely to follow.